Updated on 26 October 2026
R&D for Rare Disease Precision Medicine
CEO at Genorare
Zurich, Switzerland
About
We are seeking project partners to collaborate on the development, validation, and deployment of privacy-preserving AI solutions for rare disease diagnosis and intelligent clinical trial matching.
We welcome collaborations with hospitals, universities, research institutes, patient organizations, pharmaceutical and biotech companies, and digital health innovators. Potential cooperation areas include:
-
Clinical validation of AI models for rare disease diagnosis
-
Federated learning and privacy-preserving health data analysis
-
Integration with hospital EHR and genomic systems
-
AI-powered patient identification and clinical trial recruitment
-
Joint R&D, grant applications, and European research projects
-
Real-world evidence generation and multi-center clinical studies
Our goal is to accelerate rare disease diagnosis and improve patient access to precision medicine while ensuring the highest standards of data privacy and regulatory compliance.
Partner types sought: Hospitals, research organizations, universities, patient advocacy groups, pharmaceutical and biotech companies, CROs, and digital health technology providers.
Topic
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
Organisation
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Miguel Ángel Armengol de la Hoz
Head of Data Science Lab | Progress and Health Foundation (FPS) | Andalusian Ministry of Health at Data Science Lab (LCD) – Progress and Health Foundation (FPS)
Sevilla, Spain
Project cooperation
Partner for clinical AI evaluation, privacy-preserving data use and in-silico patient models
- Partner seeks Consortium/Coordinator
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Arinbjörn Kolbeinsson
CEO & Co-founder at K01
Reykjavík, Iceland
Project cooperation
Explainable AI for personalised prevention and care
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Federico Baldisseri
Researcher and Project Manager in AI and Automatic Control for Healthcare at Sapienza University of Rome
Rome, Italy